Quantcast

Latest Budesonide Stories

2014-09-20 23:02:18

LifeScienceIndustryResearch.com adds “Symbicort (Asthma) - Forecast and Market Analysis to 2023” to its store. Report provides Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan and Australia. Dallas, TX (PRWEB) September 20, 2014 New PharmaPoint Drug Evaluation report, “Symbicort (Asthma) – Forecast and Market Analysis to 2023″. The asthma market saw very slow growth over the past decade, as it has become saturated with relatively efficacious...

2014-03-25 00:21:44

DUBLIN, March 25, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/s3kv36/investigation) has announced the addition of the "Investigation Report on China Budesonide Market" [http://www.researchandmarkets.com/research/s3kv36/investigation ] report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) Asthma and allergic rhinitis are both very common diseases in the world today. As the global atmosphere...

2011-06-23 19:01:00

PITTSBURGH, June 23, 2011 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that the U.S. District Court for the District of Delaware has found after trial that Mylan subsidiary Mylan Pharmaceuticals Inc. does not infringe the asserted claims of U.S. Patent No. 5,643,602 with its Abbreviated New Drug Application (ANDA) for Budesonide Capsules, 3 mg (Enteric Coated), the generic version of AstraZeneca's Entocort EC® capsules, a treatment for Crohn's disease....

2011-05-10 08:00:00

CHICAGO, May 10, 2011 /PRNewswire/ -- Meritage Pharma, Inc. announced today its proprietary oral budesonide suspension (OBS) met the primary endpoint of reduction of esophageal eosinophilia and symptoms in a Phase 2b dose-ranging clinical trial in pediatric patients with eosinophilic esophagitis (EoE), an allergic inflammatory condition of the esophagus. Results from the Pediatric Eosinophilic Esophagitis Research (PEER) study were presented by principal investigators at Digestive Disease...

2011-03-01 08:00:00

SAN DIEGO, March 1, 2011 /PRNewswire/ -- Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company, today highlighted its financial results and product development progress for the year ended December 31, 2010. "Prometheus had another record year in 2010, our 14th consecutive year of sales growth," said Joseph M. Limber, President and Chief Executive Officer of Prometheus. "In addition, we made significant progress advancing a number of internal development programs,...

2010-11-30 15:34:00

SAN DIEGO, Nov. 30, 2010 /PRNewswire/ -- Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company, announced today that it has extended its distribution agreement with AstraZeneca LP for the exclusive marketing, sales and distribution of ENTOCORT® EC (budesonide) Capsules in the United States until December 31, 2011. ENTOCORT EC is the only FDA-approved drug for the induction and maintenance of clinical remission in mild to moderate Crohn's disease...

2010-11-02 07:37:00

WILMINGTON, Del., Nov. 2, 2010 /PRNewswire-FirstCall/ -- AstraZeneca (NYSE: AZN) announced today that results from TITAN, a 12-week study of SYMBICORT® (budesonide/formoterol fumarate dihydrate) Inhalation Aerosol in African American patients with moderate to severe persistent asthma, showed significant improvement in lung function for patients taking SYMBICORT compared with those using budesonide alone.(1) Safety and efficacy results from the TITAN study(1,2) are...


Word of the Day
jument
  • A beast of burden; also, a beast in general.
'Jument' ultimately comes from the Latin 'jugum,' yoke.
Related